# Evaluating the Efficacy and Safety of Xalost S in Glaucoma Patients.

> **NCT04164459** · PHASE4 · UNKNOWN · sponsor: **Taejoon Pharmaceutical Co., Ltd.** · enrollment: 144 (estimated)

## Conditions studied

- Glaucoma

## Interventions

- **DRUG:** Xalost S
- **DRUG:** Xalatan
- **DRUG:** Taflotan-S

## Key facts

- **NCT ID:** NCT04164459
- **Lead sponsor:** Taejoon Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-19
- **Primary completion:** 2019-12
- **Final completion:** 2020-02
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2019-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04164459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04164459, "Evaluating the Efficacy and Safety of Xalost S in Glaucoma Patients.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04164459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*